Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Total Liabilities for 7 consecutive years, with $401.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 18.05% to $401.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $401.4 million through Dec 2025, up 18.05% year-over-year, with the annual reading at $401.4 million for FY2025, 18.05% up from the prior year.
  • Total Liabilities hit $401.4 million in Q4 2025 for Harmony Biosciences Holdings, up from $373.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $401.4 million in Q4 2025 to a low of $229.4 million in Q1 2021.
  • Historically, Total Liabilities has averaged $299.1 million across 5 years, with a median of $298.0 million in 2022.
  • Biggest five-year swings in Total Liabilities: tumbled 51.77% in 2021 and later increased 27.09% in 2023.
  • Year by year, Total Liabilities stood at $246.9 million in 2021, then grew by 9.76% to $271.0 million in 2022, then rose by 27.09% to $344.5 million in 2023, then dropped by 1.28% to $340.0 million in 2024, then increased by 18.05% to $401.4 million in 2025.
  • Business Quant data shows Total Liabilities for HRMY at $401.4 million in Q4 2025, $373.1 million in Q3 2025, and $334.9 million in Q2 2025.